Arimoclomol for NPC receives Rare Pediatric Disease Designation
January 19, 2018 02:16 ET
|
ORPHAZYME A/S
Company announcementOrphazyme A/SNo. 01/2018 ...
Major shareholder announcement
December 18, 2017 07:08 ET
|
ORPHAZYME A/S
Orphazyme A/SCompany announcementNo. 17/2017 ...
Orphazyme assumes sponsorship of Phase II/III sIBM trial
December 15, 2017 09:20 ET
|
ORPHAZYME A/S
Investor newsNo. 01/2017 Orphazyme assumes sponsorship of Phase II/III sIBM trial On December 14, 2017, Orphazyme A/S, University of Kansas Medical Center, and UCL announced that Orphazyme...
Stabilisation measures taken and end of stabilisation period
December 14, 2017 13:02 ET
|
ORPHAZYME A/S
Company announcementNo. 16/2017 NOT FOR RELEASE OR DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN This announcement...
Orphazyme publishes offering circular and the indicative offer price range for its IPO
November 06, 2017 03:09 ET
|
Orphazyme A/S
Company announcement
Orphazyme A/S
No. 2/2017
Ole Maaløes Vej 3
DK-2200 Copenhagen N
www.orphazyme.com
Company Registration No....